Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection

[1]  Arun J. Sanyal,et al.  非アルコール性脂肪肝炎の治療薬およびバイオマーカーの開発における課題と機会 : 米国肝臓病学会(American Association for the Study of Liver Diseases)と米国食品医薬品局の合同ワークショップの知見と推奨 , 2015 .

[2]  Y. Hirata,et al.  A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes. , 2013, Gastroenterology.

[3]  J. Jia,et al.  Update on epidemiology of hepatitis B and C in China , 2013, Journal of gastroenterology and hepatology.

[4]  F. Qu,et al.  Sphingolipids as New Biomarkers for Assessment of Delayed-Type Hypersensitivity and Response to Triptolide , 2012, PloS one.

[5]  T. Okanoue,et al.  Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy , 2011, Hepatology Research.

[6]  N. Enomoto,et al.  Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  M. Langeveld,et al.  Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice , 2009, Hepatology.

[8]  J. Shayman,et al.  Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice , 2009, Hepatology.

[9]  A. Quaglia,et al.  The impact of hepatic steatosis on the natural history of chronic hepatitis C infection , 2009, Journal of viral hepatitis.

[10]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[11]  Y. Hannun,et al.  Bioactive sphingolipids: metabolism and function This work was supported by National Institutes of Health Grants GM-43825 and CA-87584. Published, JLR Papers in Press, November 17, 2008. , 2009, Journal of Lipid Research.

[12]  N. Giltiay,et al.  Acid Sphingomyelinase Deficiency Prevents Diet-induced Hepatic Triacylglycerol Accumulation and Hyperglycemia in Mice* , 2009, Journal of Biological Chemistry.

[13]  Y. Hirata,et al.  Serine Palmitoyltransferase Inhibitor Suppresses HCV Replication in a Mouse Model , 2008 .

[14]  M. Marí,et al.  Sphingolipid signalling and liver diseases , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[15]  E. Brunt.  Pathology of fatty liver disease , 2007, Modern Pathology.

[16]  T. Asselah,et al.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.

[17]  M. Colombo,et al.  Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C , 2006, Hepatology.

[18]  T. Asselah,et al.  STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? , 2005, Gut.

[19]  M. Aoki,et al.  Host sphingolipid biosynthesis as a target for hepatitis C virus therapy , 2005, Nature chemical biology.

[20]  B. Neuschwander‐Tetri,et al.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  Yoshiyuki Suzuki,et al.  Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis , 2005, Journal of medical virology.

[22]  O. Chazouilleres,et al.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C , 2005, Hepatology.

[23]  Infectious,et al.  Guideline of prevention and treatment of hepatitis C , 2004 .

[24]  L. Rubbia‐Brandt,et al.  Steatosis affects chronic hepatitis C progression in a genotype specific way , 2004, Gut.

[25]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[26]  J. Pawlotsky,et al.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies , 2003, Gut.

[27]  Yoshiyuki Suzuki,et al.  Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. , 2002, Journal of hepatology.

[28]  G. Norkrans,et al.  Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. , 2002, Journal of hepatology.

[29]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[30]  K. Abid,et al.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.

[31]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[32]  H. Popper.  American Association for the Study of Liver Diseases: Symposium on Toxic Hepatic Injury , 1960 .

[33]  F. Qu,et al.  Lipidomic profiling of plasma in patients with chronic hepatitis C infection , 2013, Analytical and Bioanalytical Chemistry.